Timothy C Lin1, Sara Gianella2, Tara Tenenbaum2, Susan J Little2, Martin Hoenigl2,3,4. 1. University of California, San Diego School of Medicine, La Jolla. 2. Division of Infectious Diseases, Department of Medicine, University of California, San Diego. 3. Section of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Austria. 4. Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Austria.
Abstract
Background: Treatment of acute human immunodeficiency virus (HIV) infection (AHI) decreases transmission and preserves immune function, but AHI diagnosis remains resource intensive. Risk-based scores predictive for AHI have been described for high-risk groups; however, symptom-based scores could be more generalizable across populations. Methods: Adults who tested either positive for AHI (antibody-negative, HIV nucleic acid test [NAT] positive) or HIV NAT negative with the community-based San Diego Early Test HIV screening program were retrospectively randomized 2:1 into a derivation and validation set. In the former, symptoms significant for AHI in a multivariate logistic regression model were assigned a score value (the odds ratio [OR] rounded to the nearest integer). The score was assessed in the validation set using receiver operating characteristics and areas under the curve (AUC). An optimal cutoff score was found using the Youden index. Results: Of 998 participants (including 261 non-men who have sex with men [MSM]), 113 had AHI (including 4 non-MSM). Compared to HIV-negative cases, AHI cases reported more symptoms (median, 4 vs 0; P < .01). Fever, myalgia, and weight loss were significantly associated with AHI in the multivariate model and corresponded to 11, 8, and 4 score points, respectively. The summed score yielded an AUC of 0.85 (95% confidence interval [CI], .77-.93). A score of ≥11 was 72% sensitive and 96% specific (diagnostic OR, 70.27). Conclusions: A 3-symptom score accurately predicted AHI in a community-based screening program and may inform allocation of resources in settings that do not routinely screen for AHI.
Background: Treatment of acute human immunodeficiency virus (HIV) infection (AHI) decreases transmission and preserves immune function, but AHI diagnosis remains resource intensive. Risk-based scores predictive for AHI have been described for high-risk groups; however, symptom-based scores could be more generalizable across populations. Methods: Adults who tested either positive for AHI (antibody-negative, HIV nucleic acid test [NAT] positive) or HIV NAT negative with the community-based San Diego Early Test HIV screening program were retrospectively randomized 2:1 into a derivation and validation set. In the former, symptoms significant for AHI in a multivariate logistic regression model were assigned a score value (the odds ratio [OR] rounded to the nearest integer). The score was assessed in the validation set using receiver operating characteristics and areas under the curve (AUC). An optimal cutoff score was found using the Youden index. Results: Of 998 participants (including 261 non-men who have sex with men [MSM]), 113 had AHI (including 4 non-MSM). Compared to HIV-negative cases, AHI cases reported more symptoms (median, 4 vs 0; P < .01). Fever, myalgia, and weight loss were significantly associated with AHI in the multivariate model and corresponded to 11, 8, and 4 score points, respectively. The summed score yielded an AUC of 0.85 (95% confidence interval [CI], .77-.93). A score of ≥11 was 72% sensitive and 96% specific (diagnostic OR, 70.27). Conclusions: A 3-symptom score accurately predicted AHI in a community-based screening program and may inform allocation of resources in settings that do not routinely screen for AHI.
Authors: Dominique L Braun; Roger D Kouyos; Belinda Balmer; Christina Grube; Rainer Weber; Huldrych F Günthard Journal: Clin Infect Dis Date: 2015-05-19 Impact factor: 9.079
Authors: Gregorio A Millett; John L Peterson; Stephen A Flores; Trevor A Hart; William L Jeffries; Patrick A Wilson; Sean B Rourke; Charles M Heilig; Jonathan Elford; Kevin A Fenton; Robert S Remis Journal: Lancet Date: 2012-07-20 Impact factor: 79.321
Authors: Patrick S Sullivan; Ulgen Fideli; Kristin M Wall; Elwyn Chomba; Cheswa Vwalika; William Kilembe; Amanda Tichacek; Nicole Luisi; Joseph Mulenga; Eric Hunter; Debrah Boeras; Susan Allen Journal: AIDS Date: 2012-01-14 Impact factor: 4.177
Authors: Maartje Dijkstra; Godelieve J de Bree; Ineke G Stolte; Udi Davidovich; Eduard J Sanders; Maria Prins; Maarten F Schim van der Loeff Journal: BMC Infect Dis Date: 2017-06-14 Impact factor: 3.090
Authors: Thomas C S Martin; Antoine Chaillon; Susannah K Graves; Timothy Lin; Sara Gianella; Davey M Smith; Susan J Little; Martin Hoenigl Journal: Clin Infect Dis Date: 2020-02-14 Impact factor: 9.079
Authors: Timothy C Lin; Maartje Dijkstra; Godelieve J De Bree; Maarten F Schim van der Loeff; Martin Hoenigl Journal: J Acquir Immune Defic Syndr Date: 2018-10-01 Impact factor: 3.731
Authors: Martin Hoenigl; Adiba Hassan; David J Moore; Peter L Anderson; Katya Corado; Michael P Dubé; Eric E Ellorin; Jill Blumenthal; Sheldon R Morris Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.771
Authors: Martin Hoenigl; Kushagra Mathur; Jill Blumenthal; Jesse Brennan; Miriam Zuazo; Melanie McCauley; Lucy E Horton; Gabriel A Wagner; Sharon L Reed; Gary M Vilke; Christopher J Coyne; Susan J Little Journal: Sci Rep Date: 2019-10-09 Impact factor: 4.379
Authors: Maartje Dijkstra; Khamisi Mohamed; Alex Kigoro; Teresia Mumba; Shally Mahmoud; Abdalla Wesonga; Nana Mukuria; Tony Oduor; Evans Gichuru; Maarten F Schim van der Loeff; Shaun Palmer; Susan M Graham; Elise M van der Elst; Eduard J Sanders Journal: Open Forum Infect Dis Date: 2021-04-29 Impact factor: 3.835
Authors: Jennifer K Felner; Maria L Mittal; Martin Hoenigl; K Rivet Amico; David J Grelotti; Alex Eanes; Kristen Hess; Jessica Crawford; Laramie R Smith Journal: J Acquir Immune Defic Syndr Date: 2021-04-15 Impact factor: 3.771
Authors: Trevor A Crowell; Justin Ritz; Robert W Coombs; Lu Zheng; Joseph J Eron; John W Mellors; Joan Dragavon; Gert U van Zyl; Javier R Lama; Kiat Ruxrungtham; Beatriz Grinsztejn; Roberto C Arduino; Lawrence Fox; Jintanat Ananworanich; Eric S Daar Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 20.999
Authors: Eduard J Sanders; Alex Kigoro; Alexander Thiong'o; Eunice Nduati; Susan M Graham Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: I Vujkovic-Cvijin; O Sortino; E Verheij; J Sklar; F W Wit; N A Kootstra; B Sellers; J M Brenchley; J Ananworanich; M Schim van der Loeff; Y Belkaid; P Reiss; I Sereti Journal: Nat Commun Date: 2020-05-15 Impact factor: 14.919